BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1646663)

  • 1. IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation.
    Duncombe AS; Grundy JE; Prentice HG; Brenner MK
    Bone Marrow Transplant; 1991 Feb; 7(2):81-7. PubMed ID: 1646663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased production of cytokines after cytomegalovirus infection of marrow-derived stromal cells.
    Lagneaux L; Delforge A; Snoeck R; Stryckmans P; Bron D
    Exp Hematol; 1994 Jan; 22(1):26-30. PubMed ID: 7506672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation.
    Kelsey SM; Newland AC
    Bone Marrow Transplant; 1989 Sep; 4(5):543-6. PubMed ID: 2551435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors.
    Lang P; Griesinger A; Hamprecht K; Feuchtinger T; Schumm M; Neuhäuser F; Greil J; Martin D; Handgretinger R; Niethammer D
    Hum Immunol; 2004 May; 65(5):423-31. PubMed ID: 15172441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection after bone marrow transplantation in children.
    Castagnola E; Cappelli B; Erba D; Rabagliati A; Lanino E; Dini G
    Hum Immunol; 2004 May; 65(5):416-22. PubMed ID: 15172440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1).
    Duncombe AS; Grundy JE; Oblakowski P; Prentice HG; Gottlieb DJ; Roy DM; Reittie JE; Bello-Fernandez C; Hoffbrand AV; Brenner MK
    Blood; 1992 Jun; 79(11):3059-66. PubMed ID: 1316791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
    Funada H; Harada M; Yoshida T; Hattori K
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of routine surveillance cultures for detection of CMV pneumonitis following bone marrow transplantation.
    Webster A; Blizzard B; Pillay D; Prentice HG; Pothecary K; Griffiths PD
    Bone Marrow Transplant; 1993 Nov; 12(5):477-81. PubMed ID: 8298558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.
    de Medeiros CR; Moreira VA; Pasquini R
    Bone Marrow Transplant; 2000 Aug; 26(4):443-4. PubMed ID: 10982292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.
    Hertenstein B; Hampl W; Bunjes D; Wiesneth M; Duncker C; Koszinowski U; Heimpel H; Arnold R; Mertens T
    Bone Marrow Transplant; 1995 Mar; 15(3):387-93. PubMed ID: 7599563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excessive vulnerability of herpes-infected endothelium to lymphokine-activated lymphocytes: a possible role in lethal viral pneumonitis following bone marrow transplantation.
    Vercellotti GM; Kotasek D; Jacob HS
    Trans Assoc Am Physicians; 1988; 101():310-3. PubMed ID: 2855899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.